2021
DOI: 10.1016/j.jand.2020.03.014
|View full text |Cite
|
Sign up to set email alerts
|

Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
54
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 67 publications
(55 citation statements)
references
References 43 publications
0
54
0
1
Order By: Relevance
“…Furthermore, it is important to consider the effects of modulator therapy on weight gain [33] . Despite the improvements in insulin secretion that CFTR correction might mediate, and the possible improvement in insulin sensitivity resulting from reduced inflammation, increased physical activity and better quality of life, other factors should be considered.…”
Section: Knowledge Gaps and Future Directionsmentioning
confidence: 99%
“…Furthermore, it is important to consider the effects of modulator therapy on weight gain [33] . Despite the improvements in insulin secretion that CFTR correction might mediate, and the possible improvement in insulin sensitivity resulting from reduced inflammation, increased physical activity and better quality of life, other factors should be considered.…”
Section: Knowledge Gaps and Future Directionsmentioning
confidence: 99%
“…CFTR modulators are a revolutionary treatment advance, partially restoring function to the dysfunctional, disease-causing CFTR channel, and are, therefore, likely to ameliorate undernutrition in CF. In fact, many studies have demonstrated weight gain in modulator-treated patients [28] , [29] . A recent systematic review examining 13 CFTR modulator trials performed between 2012 and 2017 found strong evidence for weight gain in ivacaftor-treated patients with a G511D mutation, but weaker evidence for weight gain with liumacaftor/tvacaftor or tezacaftor/ivacaftor treatment [29] .…”
Section: Causes Of Overweight and Obesity In People With Cfmentioning
confidence: 99%
“…In fact, many studies have demonstrated weight gain in modulator-treated patients [28] , [29] . A recent systematic review examining 13 CFTR modulator trials performed between 2012 and 2017 found strong evidence for weight gain in ivacaftor-treated patients with a G511D mutation, but weaker evidence for weight gain with liumacaftor/tvacaftor or tezacaftor/ivacaftor treatment [29] . Elexacaftor/tezacaftor/ivacaftor (ETI), approved in late 2019, was not included in the systematic review.…”
Section: Causes Of Overweight and Obesity In People With Cfmentioning
confidence: 99%
“…With the introduction of highly effective modulators we expect differences in body composition between and within patients to become more prevalent [ 54 ].…”
Section: Pharmacokinetics Of Cftr Modulators and Cf Features That May Change Pharmacokinetic Propertiesmentioning
confidence: 99%